




The relative strengths and weaknesses of Xeris Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xeris Pharmaceuticals INC compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 4.7% points. The greatest weakness of Xeris Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is 132%, being 106% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	87,483
Cost of Goods Sold	1,603
Intangible Assets	0
Liabilities, Current	27,338
Liabilities, Non-Current	0
Other Assets	13,651
Other Compr. Net Income	0
Other Expenses	-458
Other Liabilities	67,213
Other Net Income	-2,563
Other Revenues	1,627
Property and Equipment	7,853
Research and Development	60,438
Selling, General and Administrative Expense	63,061

Output Variable	Value in 1000 USD
Assets	108,987
Liabilities	94,551
Expenses	124,644
Revenues	1,627
Stockholders Equity	14,436
Net Income	-125,580
Comprehensive Net Income	-125,580
BaseVar	166,186
ECR before LimitedLiability	-92%
Economic Capital Ratio	132%